See more : HNI Corporation (HNI) Income Statement Analysis – Financial Results
Complete financial analysis of Mesoblast Limited (MESO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mesoblast Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Faze Three Limited (FAZE3Q.BO) Income Statement Analysis – Financial Results
- Vikram Thermo (India) Limited (VIKRAMTH.BO) Income Statement Analysis – Financial Results
- NYOCOR Co., Ltd. (600821.SS) Income Statement Analysis – Financial Results
- Nova Vision Acquisition Corporation (NOVVU) Income Statement Analysis – Financial Results
- Ucore Rare Metals Inc. (UURAF) Income Statement Analysis – Financial Results
Mesoblast Limited (MESO)
About Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.90M | 7.50M | 10.21M | 7.46M | 32.16M | 16.72M | 17.34M | 2.41M | 42.55M | 23.75M | 25.98M | 28.79M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Cost of Revenue | 41.07M | 54.92M | 63.57M | 85.73M | 81.50M | 75.17M | 5.51M | 12.07M | 29.76M | 23.78M | 25.43M | 21.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -35.17M | -47.42M | -53.36M | -78.28M | -49.34M | -58.45M | 11.83M | -9.65M | 12.79M | -35.00K | 546.00K | 7.52M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Gross Profit Ratio | 100.00% | -632.20% | -522.58% | -1,049.83% | -153.44% | -349.55% | 68.24% | -400.21% | 30.05% | -0.15% | 2.10% | 26.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 25.35M | 27.19M | 32.82M | 53.01M | 56.19M | 59.82M | 65.93M | 58.91M | 50.01M | 77.59M | 55.31M | 43.11M | 36.94M | 15.31M | 7.57M | 7.15M | 6.21M | 4.58M | 5.36M | 491.77K |
| General & Administrative | 23.63M | 25.37M | 27.21M | 30.87M | 25.61M | 21.63M | 21.91M | 23.01M | 22.50M | 36.17M | 26.56M | 30.73M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Selling & Marketing | 0.00 | 27.73M | 30.76M | 32.72M | 25.31M | 15.36M | 5.51M | 12.07M | 29.76M | 29.21M | 27.61M | 20.95M | 22.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.63M | 53.11M | 57.97M | 63.59M | 50.92M | 36.98M | 27.42M | 35.07M | 52.26M | 65.38M | 54.17M | 51.68M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Other Expenses | 0.00 | 0.00 | 30.76M | 32.65M | 25.23M | 15.48M | -1.31M | 10.53M | 25.92M | 122.00K | 16.49M | 15.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.98M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Cost & Expenses | 90.05M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Interest Income | 0.00 | 831.00K | 3.00K | 22.00K | 542.00K | 719.00K | 366.00K | 468.00K | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 739.79K | 704.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 19.44M | 16.91M | 10.71M | 13.33M | 11.33M | 1.83M | 0.00 | 9.31M | 10.53M | 4.33M | 0.00 | 289.00 | 14.91K | 0.00 | 0.00 | 0.00 | 542.00 | 110.09K | 107.12K |
| Depreciation & Amortization | 1.90M | 4.11M | 4.38M | 4.26M | 3.67M | 2.14M | 2.65M | 3.06M | 2.19M | 1.96M | 1.12M | 772.00K | 378.59K | 178.88K | 153.29K | 119.83K | 156.76K | 62.52K | 43.58K | 18.98K |
| EBITDA | -56.08M | -58.55M | -76.57M | -107.60M | -75.41M | -78.06M | -74.69M | -87.16M | -28.07M | -90.19M | -67.01M | -59.31M | -48.34M | 92.44M | -10.97M | -9.31M | -7.78M | -6.95M | -8.14M | -1.34M |
| EBITDA Ratio | -1,064.44% | -866.94% | -749.91% | -1,443.17% | -234.50% | -485.36% | -430.71% | -3,729.48% | -65.98% | -487.90% | -257.92% | -206.02% | -68.78% | 76.44% | -199,515.44% | -1,045.14% | -855.44% | -515.99% | -288.65% | -267.31% |
| Operating Income | -84.15M | -69.29M | -80.57M | -109.10M | -74.87M | -80.20M | -77.34M | -90.04M | -55.89M | -113.39M | -72.38M | -60.08M | -48.72M | 93.76M | -10.39M | -9.43M | -7.94M | -7.01M | -6.28M | -986.54K |
| Operating Income Ratio | -982.24% | -923.73% | -789.09% | -1,463.20% | -232.84% | -479.62% | -445.99% | -3,733.08% | -131.35% | -477.48% | -278.58% | -208.71% | -127.28% | 77.54% | -188,851.78% | -1,058.60% | -872.67% | -417.64% | -222.70% | -196.18% |
| Total Other Income/Expenses | -4.00M | -12.81M | -10.48M | 9.47M | -12.48M | -18.34M | 9.24M | -173.00K | -34.93M | -4.45M | -3.15M | 0.00 | -289.00 | -1.52M | -4.39M | -2.86M | -2.12M | -1.71M | -2.01M | -483.83K |
| Income Before Tax | -88.15M | -82.10M | -91.59M | -99.63M | -87.36M | -98.75M | -65.98M | -90.22M | -90.82M | -119.37M | -80.95M | -60.08M | -48.72M | 92.24M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Income Before Tax Ratio | -1,493.51% | -1,094.53% | -896.93% | -1,336.24% | -271.66% | -590.56% | -380.47% | -3,740.26% | -213.46% | -502.64% | -311.60% | -208.71% | -127.28% | 76.28% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| Income Tax Expense | 191.00K | -212.00K | -239.00K | -819.00K | -9.42M | -8.96M | -30.69M | -13.40M | -86.69M | 6.10M | 5.00K | 1.59M | 22.42M | 1.63M | -739.79K | 0.00 | 0.00 | -1.71M | -1.79M | -269.59K |
| Net Income | -87.96M | -81.89M | -91.35M | -98.81M | -77.94M | -89.80M | -35.29M | -76.82M | -4.13M | -119.37M | -80.96M | -61.66M | -71.15M | 90.61M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Net Income Ratio | -1,490.27% | -1,091.71% | -894.59% | -1,325.25% | -242.38% | -537.01% | -203.51% | -3,184.70% | -9.70% | -502.64% | -311.62% | -214.21% | -185.86% | 74.93% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| EPS | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.41 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| EPS Diluted | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.39 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 986.70M | 739.04M | 648.78M | 605.07M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
| Weighted Avg Shares Out (Dil) | 986.70M | 739.04M | 648.90M | 605.09M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
Mesoblast Key Opinion Leader Event Series for Investors & Analysts
Chronic Low Back Pain due to Degenerative Disc Disease Chronic Low Back Pain due to Degenerative Disc Disease
Operational Highlights and Financial Results for the Period Ended March 31, 2022
Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission Substantial Reduction in Operational Spend while Maintaining Focus on BLA Resubmission
Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip R. Krause, M.D. has joined its Board of Directors. Dr. Krause was for the past...
Operational Highlights and Financial Results for the Period Ended December 31, 2021
Mesoblast Prepares for Resubmission of Biologics License Application Mesoblast Prepares for Resubmission of Biologics License Application
Mesoblast Corporate Update and Financial Results Webcast
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the second quarter ended December 31, 2021.
Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn's Colitis After Direct Injection of Remestemcel-L by Colonoscopy
Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohn's and Colitis Organisation (ECCO) Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohn's and Colitis Organisation (ECCO)
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment of Dr. Eric Rose as the Company's Chief Medical Officer (CMO). Dr. Rose...
Mesoblast to Participate in Edison Group's Global Healthcare “Open House” Virtual Conference From January 25-27th, 2022
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it is participating in Edison Group's Open House Event, scheduled to take place virtually this week. The...
Single Dose Of Mesoblast's Cell Therapy Shows Durable Reduction In Back Pain
Mesoblast Limited (NASDAQ: MESO) announced 36-month follow-up results from the 400-subject Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L in patients with chronic low back pain (CLBP) associated with degenerative disc disease (DDD). The data showed a durable reduction in back pain...
Single Dose of Mesoblast's Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease
36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase 36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase
Source: https://incomestatements.info
Category: Stock Reports